该合资企业命名为PPD-SNBL,将由SNBL的临床研究部与PPD在日本的临床开发运营部门合并而成,将在东京、大阪和鹿儿岛设立办事处,拥有近400位临床开发专业人员。此次合并是PPD的全球临床试验专项技能与SNBL为日本生物制药公司提供临床开发服务近20年历史的结合。 根据协议条款,PPD-SNBL将由PPD控股。SNBL代表取缔役会长兼社长R...
北卡羅萊納州威明頓和東京 -- (美國商業資訊) -- Pharmaceutical Product Development, LLC (PPD)與新日本科學株式會社(SNBL) (TSE:2395)今天宣佈雙方成立合資企業的協議,以便在日本展開全套臨床開發服務,包括第一到第四期臨床試驗監測、專案管理、研究單位情報和啟動、生物統計學、資料管理、醫學撰稿、藥物主動監視、...
WILMINGTON, N.C. & TOKYO--(BUSINESS WIRE)--PPD-SNBL, the joint venture of Pharmaceutical Product Development, LLC (PPD), a leading global contract research organization (CRO), and Shin Nippon Biomedical Laboratories Ltd., one of the largest clinical development service providers in Japan, has ...
PPD and SNBL Announce Japanese Joint Venture
PPD and SNBL Announce Japanese Clinical Development Joint Venture and Additional Collaborations
Under the terms of the agreement, PPD-SNBL will be majority owned by PPD. Ryoichi Nagata M.D., Ph.D., chairman and president of SNBL, will serve as the president of the joint venture. The parties have also entered into an agreement under which they will collaborate in a number of area...